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ToTem: a Phase Ib trial of temisirolimus with gemcitabine and cisplatin 
 
Background: a combination of gemcitabine (G) and cisplatin (C) is a 
standard-of-care, systemic anti-cancer therapy regimen for neoadjuvant 
treatment of muscle-invasive and palliative treatment of advanced bladder 
cancer (BC).  There is a pressing need for more effective chemotherapy 
regimens, but there have been no significant improvements on this regimen 
for more than a decade. mTOR is a rational target for treatment of bladder 
cancer, as abnormalities are commonly observed in mTOR’s upstream 
activators or downstream effectors, within the PI3K/Akt/mTOR signaling 
pathway.  We have therefore performed a Phase Ib trial, combining escalating 
doses of the mTOR inhibitor, temsirolimus (T) with GC. 
Methods: following regulatory and ethical approvals, eligible patients with 
advanced malignancy were treated with escalating doses of intravenous (IV) 
temsirolimus (T) in combination with fixed doses of IV GC, in a 21-day cycle.  
Previous unpublished data suggest a possible interaction between G and T.  
We therefore pursued a cautious dose escalation strategy, as in the table 
below, as a precaution against excessive toxicity. 
 
 
 
 
Cohort  Cisplatin 
(Day 1) 
Gemcitabine 
(Day 1, 8) 
Temsirolimus 
D1 D2 D8 D9 D15 
1 70 mg/m2 1000 mg/m2     10mg 
2 70 mg/m2 1000 mg/m2   10mg  10mg 
3a 70 mg/m2 1000 mg/m2 10mg  10mg  10mg 
3b 70 mg/m2 1000 mg/m2  10mg  10mg 10mg 
 
Results: 14 patients have been treated, at 4 dose schedules in 2 UK centres.  
There have been no treatment-related deaths or SUSARs. There were 14 
SAEs, of which 4 were SARs, in 10 individuals, 7 of whom had received IMP.  
Addition of 10mg T on days 15, then 8 and 15 was tolerated, but DLTs were 
encountered when administering three 10mg doses of T, both on days 1, 8 
and 15 (neutropenia; hypokalaemia) and days 2, 9 and 15 (febrile 
neutropenia; rash). 
Conclusions: it has not been feasible to add three, weekly doses of T to GC, 
even at low T doses, in the patient group tested, because of predominantly 
haematological toxicity.  Forthcoming pharmacokinetic analyses will inform a 
planned amendment to the scheduling of T in combination with GC 
 
ToTem was: developed by the UK NIHR Bladder Cancer Clinical Studies 
Group; sponsored by Cardiff University; funded by Cancer Research UK; and 
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